抄録
In boron neutron capture therapy (BNCT), the most critical challenge is how to selectively and sufficiently deliver 10B boron atoms to tumor tissues. For this reason, the development of boron–containing agents for BNCT, which serve as carriers of 10B atoms, is regarded as one of the fundamental technologies underpinning BNCT. However, at present, only a single BNCT agent has been approved as a pharmaceutical product. Several factors may account for this situation, and one of them is considered to be the evaluation criteria applied to BNCT boron agents, which differ from those used in conventional drug development and place emphasis on tumor accumulation and selectivity. In this article, we provide an overview of these evaluation approaches unique to BNCT boron agents.
